Treatments for malaria, sleeping sickness and Chagas disease added to WHO's list of pediatric medicines
The World Health Organization has released its updated Model List for Essential Medicines for Children (EMLc) including three treatments developed by the Drugs for Neglected Diseases initiative (DNDi) and its partners. The treatments will improve the management of deadly malaria, African sleeping sickness, and Chagas disease in children.
The three pediatric drugs added to the 4th EMLc include Artesunate-mefloquine fixed-dose combination (ASMQ FDC) for the treatment of malaria in children. It was also added to the 18th WHO EML for adults. ASMQ FDC was developed with Brazil’s state pharmaceutical group Farmanguinhos/Fiocruz and launched first in Brazil in 2008. After a technology transfer to Indian drugmaker Cipla (BSE: 500087), ASMQ FDC was prequalified by the WHO in 2012, and registered in India, Malaysia, and Myanmar in 2011-2013.
First new treatment for sleeping sickness in 25 years
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze